Yantai Zhenghai Bio-Tech Co Ltd
Yantai Zhenghai Biotechnology Co., Ltd. engages in the research and development, production, and sales of bioregenerative medical materials in China. The company offers oral repair membranes, absorbable dura mater patches, active biological bones, skin repair membranes, bone repair materials, surgical packing sponges, phosphoric acid etchant, dental pit and fissure sealant, light-curing composite… Read more
Market Cap & Net Worth: Yantai Zhenghai Bio-Tech Co Ltd (300653)
Yantai Zhenghai Bio-Tech Co Ltd (SHE:300653) has a market capitalization of $493.59 Million (CN¥3.62 Billion) as of March 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #13403 globally and #3435 in its home market, demonstrating a 0.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Yantai Zhenghai Bio-Tech Co Ltd's stock price CN¥20.12 by its total outstanding shares 180000000 (180.00 Million).
Yantai Zhenghai Bio-Tech Co Ltd Market Cap History: 2017 to 2026
Yantai Zhenghai Bio-Tech Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $341.77 Million to $493.59 Million (13.17% CAGR).
Yantai Zhenghai Bio-Tech Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Yantai Zhenghai Bio-Tech Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.44x
Yantai Zhenghai Bio-Tech Co Ltd's market cap is 1.44 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
3.88x
Yantai Zhenghai Bio-Tech Co Ltd's market cap is 3.88 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $341.77 Million | $182.78 Million | $61.67 Million | 1.87x | 5.54x |
| 2018 | $457.90 Million | $215.54 Million | $85.82 Million | 2.12x | 5.34x |
| 2019 | $705.41 Million | $279.81 Million | $107.39 Million | 2.52x | 6.57x |
| 2020 | $856.93 Million | $293.28 Million | $118.33 Million | 2.92x | 7.24x |
| 2021 | $1.01 Billion | $400.18 Million | $168.55 Million | 2.53x | 6.02x |
| 2022 | $1.00 Billion | $433.22 Million | $185.44 Million | 2.31x | 5.40x |
| 2023 | $686.93 Million | $413.65 Million | $190.96 Million | 1.66x | 3.60x |
| 2024 | $522.54 Million | $363.23 Million | $134.64 Million | 1.44x | 3.88x |
Competitor Companies of 300653 by Market Capitalization
Companies near Yantai Zhenghai Bio-Tech Co Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Yantai Zhenghai Bio-Tech Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Yantai Zhenghai Bio-Tech Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Yantai Zhenghai Bio-Tech Co Ltd's market cap moved from $341.77 Million to $ 493.59 Million, with a yearly change of 13.17%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥493.59 Million | +0.75% |
| 2025 | CN¥489.91 Million | -6.24% |
| 2024 | CN¥522.54 Million | -23.93% |
| 2023 | CN¥686.93 Million | -31.41% |
| 2022 | CN¥1.00 Billion | -1.23% |
| 2021 | CN¥1.01 Billion | +18.33% |
| 2020 | CN¥856.93 Million | +21.48% |
| 2019 | CN¥705.41 Million | +54.05% |
| 2018 | CN¥457.90 Million | +33.98% |
| 2017 | CN¥341.77 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Yantai Zhenghai Bio-Tech Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $493.59 Million USD |
| MoneyControl | $493.59 Million USD |
| MarketWatch | $493.59 Million USD |
| marketcap.company | $493.59 Million USD |
| Reuters | $493.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.